Page 134 - Read Online

Hershman. J Cancer Metastasis Treat 2022;8:3 Journal of Cancer
DOI: 10.20517/2394-4722.2021.156
Metastasis and Treatment

Editorial Open Access

New developments in management of metastatic
thyroid cancer

Jerome M. Hershman

Department of Medicine, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA 90073, USA.
Correspondence to: Prof. Jerome M. Hershman, Department of Medicine, David Geffen School of Medicine, University of
California-Los Angeles, 11301 Wilshire Blvd, Los Angeles, CA 90073, USA. E-mail: jhershmn@g.ucla.edu

How to cite this article: Hershman JM. New developments in management of metastatic thyroid cancer. J Cancer Metastasis
Treat 2022;8:3. https://dx.doi.org/10.20517/2394-4722.2021.156

Received: 3 Aug 2021 Accepted: 9 Aug 2021 Published: 25 Jan 2022

Academic Editors: Lucio Miele, Alessandro Antonelli Copy Editor: Xi-Jun Chen Production Editor: Xi-Jun Chen

[1]
Thyroid cancer is increasing in prevalence . Despite the use of ultrasonography for detection in an early
phase, aggressive variants leading to metastatic disease continue to occur in perhaps 5% of patients . This
[2]
issue of the Journal of Cancer Metastasis and Treatment focuses on thyroid cancer. The ten timely review
articles provide an excellent overview of selected aspects of metastatic thyroid cancer.

Davidson and Carr provide a thorough review of thyroid cancer metabolism and the principal pathways
[3]
leading to thyroid cancer with superb illustrations of the various metabolic pathways. In addition, this
article reviews the various pharmacologic inhibitors of the pathways, thus providing the reader with an
efficient source for comprehending the extensive literature in this field.

Autophagy plays an important role in the homeostasis and survival of thyroid cells. Nagayama provides a
very thorough review of the role of autophagy in thyroid cancer and defines the need for additional
[4]
pharmacologic studies that target this pathway in thyroid cancer cells .
Anaplastic thyroid cancer (ATC) is still a rapidly deadly tumor without any established therapy. Lee and
Cheng present elegant studies of transcriptional pathways to explain transcriptional addiction that makes
[5]
this tumor so difficult to treat effectively. They propose the use of small molecule inhibitors to target the
transcriptional regulators in ATC.

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0
International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing,
adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as
long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and
indicate if changes were made.

www.jcmtjournal.com